Data Demonstrates Potential for the Company’s Intranasal Vaccine to Combat Reemergence of Whooping Cough Infections
ANN ARBOR, Mich., (July 27, 2016) – NanoBio Corporation today announced that the company will present key data at the Mucosal Immunology Course & Symposium Meeting (MICS) in Toronto on July 29, 2016, demonstrating the advantages of its intranasal nanoemulsion (NE) adjuvant for use in the development of vaccines for pertussis, commonly known as whooping cough. NanoBio will also present data further supporting the advantages of intranasal NE vaccines for pandemic influenza.
“The resurgence of pertussis infections in the United States and worldwide has become quite concerning, as infections in the U.S. have recently reached a 50-year peak. Given vaccination rates have remained high, the concerning increase in infections points to potential limitations with the existing intramuscular pertussis vaccines,” said Dr. Ali Fattom, Senior Vice President of Vaccine Research and Development, NanoBio. “We recently tested an intranasal NE pertussis vaccine in animals and the data indicates important benefit in comparison to current intramuscular vaccines. NanoBio’s vaccine elicited robust systemic immunity and triggered a mucosal immune response believed to be critical in reducing the time pertussis is carried in the respiratory tract of individuals exposed to the bacteria. A reduction of carriage would lead directly to lower rates of transmission.”
At the MICS conference, NanoBio will present data from a study in rats comparing its intranasal NE pertussis vaccine to the standard intramuscular Alum vaccine. The research indicated that both vaccines elicited similarly high levels of serum bactericidal activity against pertussis. However, the intranasal NE vaccine uniquely elicited high levels of cytokines that are associated with mucosal immunity. Given the promising results, efficacy of the intranasal NE pertussis vaccine is currently being studied in a baboon challenge model with support from the National Institutes of Health (NIH).
NanoBio will also present data at the MICS meeting highlighting results from a mice study testing an intranasal NE vaccine for pandemic influenza. The research being presented was conducted under a five-year contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH.
“Our recent studies in mice have demonstrated that intranasal NE vaccination elicits robust neutralizing antibody and cellular immune responses against H5 pandemic influenza,” said Dr. Fattom. “In addition, the intranasal NE-rH5 vaccine uniquely elicited a mucosal immune response, which we expect will play an important role in protecting against H5 infection. With these results in hand, we are currently initiating a ferret challenge study to test the efficacy of the NE vaccine in the primary animal model.”
Following are details of NanoBio’s upcoming oral presentations at the MICS Meeting at the Westin Harbour Castle Hotel, Toronto, Canada:
- Nanoemulsion: A Novel Mucosal Adjuvant for Pandemic H5N1 Influenza
Friday, July 29, 2016 / 3:30 p.m. ET
- Intranasal Nanoemulsion-Based Vaccines for the Elicitation of Mucosal and Systemic Immunity to Combat Reemergence of B. Pertussis Infections
Friday, July 29, 2016 / 3:45 p.m. ET
Headquartered in Ann Arbor, Michigan, NanoBio® Corporation is a privately-held biopharmaceutical company focused on developing and commercializing vaccines and anti-infective treatments derived from its patented NanoStat® technology platform. The company’s NanoStat® vaccine technology employs a novel oil-in-water nanoemulsion (NE) that can incorporate, deliver and adjuvant multiple antigen types. The NE adjuvant is effective when administered via intranasal or intramuscular vaccination. When applied intranasally, NE vaccines elicit both mucosal and systemic immunity.
NanoBio is currently developing NE vaccines for several respiratory and sexually transmitted diseases, including pertussis, pandemic influenza, anthrax, prophylactic and therapeutic HSV2, chlamydia and HIV. In addition, the company has licensed its NE adjuvant to Merck for use with intranasal vaccines for RSV and seasonal influenza.